{"id":"W4391288586","doi":"10.1016/j.ejca.2024.113580","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Veliparib; Carboplatin; Paclitaxel; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Biology; Cisplatin; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001559295,0.0003121614,0.001072958,0.0002744562,0.00004469054,0.00008752309,0.0001220924,0.00005100186,0.000355977],"category_scores_gemma":[0.0001579245,0.0002190062,0.0001913225,0.0003382705,0.0002087335,0.0002804248,0.00002438461,0.0007810088,0.000005637642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003346668,"about_ca_system_score_gemma":0.0007359908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004641055,"about_ca_topic_score_gemma":0.0001705458,"domain_scores_codex":[0.9966338,0.00075697,0.001246252,0.0003996433,0.0006443884,0.0003189853],"domain_scores_gemma":[0.9982505,0.0004690097,0.0005357942,0.000194252,0.0002834666,0.0002669086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9426694,0.0001582117,0.0001268914,0.00005144407,0.000676153,0.001844116,0.001689759,0.000587523,0.007714389,0.00001945099,0.001850414,0.04261227],"study_design_scores_gemma":[0.978718,0.001129343,0.004045166,0.004009203,0.0004548844,0.0002791008,0.0001215501,0.0008029095,0.0009399207,0.0000843303,0.009117629,0.0002979716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9700507,0.01942082,0.0003612585,0.005509485,0.001521403,0.0007126043,0.0007313135,0.00004521187,0.001647188],"genre_scores_gemma":[0.9916357,0.004543741,0.0005013446,0.000473412,0.002082737,0.00003326116,0.00002571773,0.00008676601,0.0006173665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04231429,"threshold_uncertainty_score":0.8930815,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03210246603371406,"score_gpt":0.346698349754391,"score_spread":0.3145958837206769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}